Evaluation of metrics derived from continuous interstitial glucose monitoring of patients using disease modifying drugs in type 2 diabetes.

Abstract

Introduction: the use of disease-modifying drugs such as aGLP1 and iSGLT-2 has proven to be key in the treatment of patients with type 2 diabetes. Additionally, continuous glucose monitoring (CGM) through standardized metrics offers better glycemic control, contributing to the management and/or regression of microvascular complications of diabetes. The aim of this study was to evaluate the therapeutic outcomes of disease-modifying drugs through the metrics derived from CGM in patients with type 2 diabetes who attended the Endocrinology service at the La Trinidad Medical Teaching Center between February and October 2024. Methods: the study, exploratory, descriptive, and analytical retrospective in nature, included 33 patients with type 2 diabetes treated with disease-modifying drugs and using CGM. Results: the analysis showed that 69.7% of patients maintained time in range (TIR), 72.73% maintained time below range (TBR) within the target, and only 27.27% remained with time above range (TAR). In addition, glycemic variability was below 36%, indicating adequate glycemic control in most patients. Conclusions: the combined use of CGM and aGLP1 and iSGLT2 drugs proved to be a key factor in glycemic control and chronic microvascular complications of diabetes.